Table 4 Incremental costs and QALYs (with 95% CI), associated incremental cost-effectiveness ratios, and the probability of simvastatin being cost-effective compared to placebo at a threshold willingness to pay/QALY of £20,000 for the base case and sensitivity analyses

Primary analysis (unadjusted) (simvastatin n = 139, placebo n = 153^b)

–3600.91 (–8061.10 to 859.28)

0.064 (0.002 to 0.127)

99%

Adjusted for baseline variables (simvastatin n = 139, placebo n = 153^b)

–2661.03 (–7842.76 to 2520.70)

0.089 (0.025 to 0.151)

95%

Multiply imputed total costs and QALYs (simvastatin n = 259, placebo n = 280^c)

–2132.69 (–5629.21 to 1363.83)

0.042 (–0.001 to 0.086)

96%

Multiply imputed total costs and QALY, adjusted (simvastatin n = 259, placebo n = 280^c)

–1290.35 (–5000.61 to 2419.91)

0.048 (0.005 to 0.091)

90%

Death as a censoring event (simvastatin n = 74, placebo n = 68^b)

–8532.48 (–16107.75 to –957.21)

0.056 (–0.022 to 0.135)

99%

No mean imputation of care data (simvastatin n = 137, placebo n = 151^b)

–3966.00 (–8503.11 to 571.10)

0.066 (0.004 to 0.128)

99%

QALY calculation using discharge, 3-, 6-, and 12-month EQ-5D-3 L (simvastatin n = 138, placebo n = 150^b)

–3559.00 (–8241.41 to 1123.42)

0.084 (0.005 to 0.162)

99%